This inventor holds 1 USPTO granted patent. Top assignee: Eberhard-Karls-Universität Tübingen Universitätsklinikum. Active years: 2005.
Company Filing History:
Years Active: 2005
Title: Innovations of Charles Cant in Antibody Development
Introduction
Charles Cant is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on the interaction of signal regulator proteins, which has implications for various therapeutic applications.
Latest Patents
Charles Cant holds a patent for "Antibodies directed against signal regulator proteins." This patent describes monoclonal antibodies that specifically bind to the extracellular domain of the SIRP cell surface glycoproteins. In some cases, these antibodies block the interaction of SIRP with the surface molecule CD47. This innovation has the potential to advance treatments in immunology and cancer therapy. He has 1 patent to his name.
Career Highlights
Charles Cant is affiliated with the Eberhard-Karls-Universität Tübingen Universitätsklinikum, where he conducts his research. His work has been instrumental in understanding the mechanisms of immune regulation and the development of targeted therapies.
Collaborations
Throughout his career, Charles has collaborated with esteemed colleagues such as Axel Ullrich and Hans-Jörg Bühring. These partnerships have enriched his research and contributed to the advancement of knowledge in the field.
Conclusion
Charles Cant's innovative work in antibody development showcases the importance of research in biotechnology. His contributions are paving the way for new therapeutic strategies that could significantly impact patient care.